Eye Drugs Flashcards
Causes of Mydriasis
Low light
Muscarinic Antagonists
Sympathetic Stimulation (weak)
Alpha 1 agonists (weak)
Causes of Miosis
High light
Parasympathetic stimulation (weak)
Muscarinic Agonists
Alpha 1 antagonists (weak)
Drug Absorption
Generally topical- minimise adverse systemic effects
Slow release formulations: reduce risk of SEs
Uncharged and lipophilic to cross cornea
Nasolachrymal Drainage: Key in systemic absorption
Circumvents hepatic first-pass metabolism
Eye Colour
Increased Melanin causes drugs to bind
Slower onset and longer duration
Ophthalmic Diagnosis
Mydriatics used to look at fundus
Muscarinic antagonists: Topicramide, 1-3 hours duration, little cycloplegia
Adrenaline is less effective but no cycloplegia via alpha1
Glaucoma
Poor drainage of aqueous humour (Canal of Schlemm)
Increased intraocular pressure- >21mmHg
Changes to fundus (optic disc cupping)
Can cause permanent damage to optic nerve
Open angle and closed angle
Open-Angle Glaucoma- Dec. Production
Beta-Blockers- Timolol- decreases blood flow in ciliary body
Caution- OLD, Asthma, Bradycardia, HF due to systemic absorption
Carbonic Anhydrase Inhibitor- Dorzolamide- Dec. HCO3- leading to dec Na+ and aqueous formation
Open-Angle Glaucoma- Inc. Drainage
Miotics-Pilocarpine- Increases uveoscleral outflow
SE: Long-term pupil constriction, accomodatin spasm- blurred vision, headaches
Prostaglandin- Lanaprost- PGF2alpha analogue, increase drainage
Alpha-2 Agonists
Brimonidine- Chronic open-angle when other agents ineffective
Used alone or with Beta-Blocker
MOA: Decrease aqueous humour production- vasoconstriction
Increased uveoscleral outflow- prostaglandin release
Closed-Angle Glaucoma
Cut hole in Iris
Mydriatics may make it worse by reducing drainage
Age-Related Macular Degeneration
Affects elderly: Most common blindness in UK
Cause unknown: Central retinal pathways deteriorate- dry
10% have neovascular “wet” AMD. New blood vessels leak under retina and can be rapid onset
Wet AMD Therapy
Photodynamic therapy- Verteporfin taken up by endothelium, apply laser, free radicals destroy new vessels
VEGF MAb- Ranizumab- binds and inhibits VEGF in retina, slowing progression